DMD Noab BioDiscoveries - Shaping Drug Discovery

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wong, S. G.W.
Right arrow Articles by Marks, G. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wong, S. G.W.
Right arrow Articles by Marks, G. S.

Vol. 26, Issue 8, 739-744, August 1998

Gender Differences in N-Alkyl Protoporphyrin IX Production in Rats after the Administration of Porphyrinogenic Xenobiotics

Simon G.W. Wong, Susan M. Kobus, James P. McNamee, and Gerald S. Marks

Department of Pharmacology and Toxicology, Faculty of Medicine, Queen's University

    Abstract
Top
Abstract
Introduction
Materials & Methods
Results & Discussion
References

The porphyrinogenicity of 3-[(arylthio)ethyl]sydnone (TTMS) and 3,5-diethoxycarbonyl-1,4-dihydro-2,6-dimethyl-4-ethylpyridine (4-ethylDDC) in rats is dependent on mechanism-based inactivation of selected isozymes of hepatic cytochrome P450 (P450), namely P4501A1/2, 2C6, 3A, and 2C11, followed by formation of ferrochelatase-inhibitory N-alkyl protoporphyrin IX (N-alkylPP). The objective of this study was to determine which P450 isozymes were sources of the N-alkylPPs. Previously, selective inhibition of male rat P4503A showed that it was the major source of N-vinylprotoporphyrin IX after TTMS administration. In the present study, when TTMS was administered to female rats, which lack P4503A2 and 2C11, N-vinylPP formation was 2.3% of that produced by males, which have both of these isozymes. Therefore, although P4503A2 is a major source, P4502C11 is also a significant source of N-vinylPP in males. Selective inhibition of P4503A and 1A1/2 did not decrease N-ethylPP formation in response to 4-ethylDDC administration to male rats, showing that P4503A and 1A1/2 were not sources of N-ethylPP. Thus P4502C6 and 2C11 were the remaining isozyme candidates to be investigated. When 4-ethylDDC was administered to female rats, N-ethylPP formation was 22% of that produced by males. Because female rat livers contain P4502C6 but lack the male specific P4502C11, the likely origin of N-ethylPP in females is P4502C6. Because males produced markedly more N-ethylPP than females, and males have P4502C11 in addition to P4502C6, we conclude that P4502C11 is the major source of N-ethylPP in males, whereas P4502C6 may also be a significant contributor.

    Introduction
Top
Abstract
Introduction
Materials & Methods
Results & Discussion
References

Porphyrinogenic xenobiotics are compounds that interfere with heme biosynthesis, resulting in an accumulation of porphyrins and other heme precursors and producing a condition known as experimental porphyria (De Matteis and Marks, 1996). A variety of these agents, including dihydropyridines, dihydroquinolines, and sydnones, cause mechanism-based inactivation of selected hepatic cytochrome P450 (P450)1 isozymes, which is a critical event in their porphyrinogenicity (De Matteis and Marks, 1996; McNamee and Marks, 1996; Riddick et al., 1989; Coffman et al., 1982; Ortiz de Montellano et al., 1981a; Riddick et al., 1990; Marks et al., 1988). Mechanism-based P450 inactivation can involve three distinct mechanisms: (a) N-alkylation of the heme moiety, resulting in N-alkylprotoprophyrin IX (N-alkylPP) formation, (b) alkylation of the apoprotein, or (c) conversion of the heme moiety to products that covalently bind the heme apoprotein (Halpert et al., 1994). N-AlkylPPs (fig. 1) are potent inhibitors of the terminal enzyme in heme biosynthesis (ferrochelatase, EC 4.99.1) (Marks et al., 1985; McCluskey et al., 1986; McCluskey et al., 1988; Ortiz de Montellano et al., 1980; Ortiz de Montellano et al., 1981c; Tephly et al., 1979) and only when mechanism-based P450 inactivation is accompanied by N-alkylPP formation does inhibition of ferrochelatase occur, leading to elevation of hepatic protoporphyrin IX (De Matteis and Marks, 1996).


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 1.   Structure of an N-alkylprotoporphyrin IX.

The NA regioisomer is shown. For N-ethylPP, R = -CH2-CH3. For N-vinylPP, R = -CH=CH2.

Development of the potent anti-arthritic compound 3-[(arylthio)ethyl]sydnone (TTMS) was abandoned when it was shown to cause hepatic protoporphyrin IX accumulation in dogs and rodents (Stejskal et al., 1975). These observations were attributed to mechanism-based inactivation of P450 with concurrent N-vinylPP formation, inhibition of ferrochelatase, and an induction of aminolevulinic acid synthase activity, all of which are hallmarks of experimental porphyria (Sutherland et al., 1986; Ortiz de Montellano and Grab, 1986). Studies in our laboratory indicated that P4501A, 3A, 2B1, 2C6, and 2C11 were targeted for mechanism-based inactivation by TTMS (McNamee and Marks, 1996). Because only those isozymes undergoing N-alkylation would contribute to the porphyrinogenicity of TTMS, our next studies were directed to determining the P450 isozyme or isozymes responsible for N-vinylPP production. This goal was pursued by comparing selective P450 isozyme induction and inhibition with hepatic N-vinylPP production in rats. In untreated (UT) rats, co-administration of troleandomycin (TAO), a selective P4503A inhibitor (Chang et al., 1994), with TTMS resulted in a 66% decrease in N-vinylPP formation (McNamee and Marks, 1996). Conversely, induction of P4501A with beta NF did not affect N-vinylPP production. On the basis of the above induction and inhibition studies, P4503A was identified as the major source of N-vinylPP production, and P4501A was eliminated as a possible source of N-vinylPP.

Assuming that P4503A contributed approximately 66% to total N-vinylPP formation, the remaining 34% was considered to originate from the other P450 isozymes that are mechanistically inactivated by TTMS, namely P450 2B1, 2C6, and/or 2C11. Limitations in the selectivity of P450 inducers and inhibitors (Halpert, 1995; Roos and Mahnke, 1996), in addition to the poor inducibility of P4502C6 and 2C11 (Guengerich et al., 1982; Waxman et al., 1985; Shimada et al., 1989), prompted the exploration of alternative methods to determine which of these isozymes were quantitatively important for the production of N-vinylPP. We decided on an alternative research plan, which takes advantage of the marked gender difference in P450 isozyme expression in rodents (Cooper et al., 1993; Ghosal et al., 1996; Gonzalez et al., 1986; Waxman, 1988; Zaphiropoulos et al., 1989). Male rat livers contain large amounts of P4503A2 and 2C11, whereas only trace amounts of these isozymes are present in female rat liver (Cooper et al., 1993; Ghosal et al., 1996). Because of these gender differences in P450 isozyme profiles, and because P4503A2 was determined to be a major source of N-vinylPP in male rats, we anticipated marked differences between male and female rats in N-vinylPP production in response to TTMS administration. Our first objective was to use these gender differences in P450 isozyme expression to determine the relative contributions of P4502C11 and 3A2 to the production of N-vinylPP.

The dihydropyridine, 4-ethylDDC, is another classical porphyrinogenic drug for which the mechanism involves the N-alkylation of heme, resulting in the production of N-ethylPPs (Riddick et al., 1990; Ortiz de Montellano et al., 1981a; Ortiz de Montellano et al., 1981b; De Matteis et al., 1980; Tephly et al., 1979). 4-EthylDDC causes mechanism-based inactivation of rat P4501A, 2C6, 2C11, and 3A (Kimmett et al., 1994; Riddick et al., 1989; Tephly et al., 1986; Correia et al., 1987). Our second objective was to determine which of these isozymes, or combination of isozymes, were the sources of N-ethylPP. The experimental procedure employed was to use selective inducers/inhibitors of P450 isozymes, and to compare N-ethylPP formation in response to 4-ethylDDC administration between male and female rats.

    Materials and Methods
Top
Abstract
Introduction
Materials & Methods
Results & Discussion
References

Reagents and Chemicals. TTMS and 4-ethylDDC were obtained from Color Your Enzyme (Bath, Ontario, Canada). Solvents (methanol, dichloromethane, and acetone) were purchased from VWR Canada (Mississauga, Ontario, Canada). Inhibitors (alpha NF and TAO) and inducers (beta NF, DEX, and PB) were purchased from Sigma Chemical Co. (St. Louis, MO).

Treatment of Animals. For the inducer and inhibitor studies, male Sprague-Dawley rats (200-250g) were obtained from Charles River Canada, Inc. (St. Constant, Quebec, Canada). For the gender studies, male and female rats (150-200 g) were obtained. All rats received Ralston Purina Laboratory Chow (no. 5001; Ren's Feed and Supplies, Ltd., Oakville, Ontario, Canada) and water ad libitum and were housed under controlled conditions (22oC, 14-hr/10-hr light/dark cycle). Animals were allowed a 1-week environmental adjustment period.

Induction Study. Rats received the appropriate inducer, dissolved in 0.5 ml vehicle, intraperitoneally once daily for either 3 days (beta NF) or 4 days (DEX and PB). The vehicle for beta NF (40 mg/kg) and DEX (100 mg/kg) was DMSO:corn oil (1:7 v/v), and for PB (80 mg/kg) it was deionized water. Control animals received DMSO:corn oil (1:7 v/v) once daily for four days.

Inhibitor Studies. The inhibitor TAO (450 mg/kg) was co-administered with TTMS (111.3 mg/kg) or 4-ethylDDC (400 mg/kg) 24 hr after the final dose of DEX or vehicle. alpha -Naphthoflavone (alpha NF) (100 mg/kg) was co-administered with 4-ethylDDC (400 mg/kg) 24 hr after the final dose of beta NF or vehicle.

Isolation, Purification, and Separation of N-AlkylPP. Four hours after administration of porphyrinogenic compounds, in the presence or absence of inhibitor, rats were decapitated and their livers perfused in situ with 100 ml ice-cold 1.15% potassium chloride solution. Livers were individually weighed and homogenized in ice-cold 5% H2SO4:methanol (v/v; 100 ml/liver), and stored in the dark at 4oC for 24 hr. The resulting N-alkylPP dimethyl ester mixture was filtered, diluted with an equal volume of deionized water, and then extracted with dichloromethane (2 × 30 ml) in a separatory funnel. After successive washes with 5% sodium bicarbonate (80 ml) and deionized water (2 × 80 ml) the dichloromethane solution was dried over anhydrous sodium sulfate. After removal of the sodium sulfate by filtration, zinc acetate (25 µmol) in methanol (2 ml) was added to form the Zn N-alkylPP dimethyl ester, and the solution was evaporated to dryness. The residue was dissolved in dichloromethane and applied to an Analtech silica gel G TLC plate (2,000 µm; Newark, DE) and developed in dichloromethane:methanol (13:2) for 60 min. A single green band (Rf 0.68-0.74) that fluoresced red under long-wavelength UV light was eluted from the plate with acetone and evaporated to dryness. The residue was dissolved in dichloromethane, applied to a second Analtech silica gel G plate (1000 µm) and developed in dichloromethane:acetone (5:1) for 45-50 min. Two green bands, at Rf 0.69-0.72 and Rf 0.75-0.77, that fluoresced red under long wavelength UV light were eluted together, with acetone. The electronic absorption spectrum was determined using an Hewlett-Packard 8451A diode array spectrophotometer (Mississauga, Ontario, Canada). The concentration of the Zn N-alkylprotoporphyrin dimethyl ester was determined using the molar extinction coefficient for Zn N-methylPP dimethyl ester (epsilon  = 124,000 m-1cm-1 at 432 nm) (Ortiz de Montellano et al., 1981b).

Statistical Analysis. For the induction study (fig. 3), a randomized design one-way analysis of variance with a Newman-Keul's post hoc test was used to determine if means were significantly different (p < 0.05). For the male-female rat gender studies (fig. 2) an unpaired Student's t test was used to determine if mean values of male and females were significantly different (p < 0.05). For the inhibitor studies with TAO or alpha NF, an unpaired Student's t test was used to determine if the mean data of inhibitor-treated rats was significantly different (p < 0.05) from the control animals receiving no inhibitor.


View larger version (11K):
[in this window]
[in a new window]
 
Fig. 2.   N-VinylPP and N-ethylPP formation in male and female rat liver after administration of TTMS and 4-ethylDDC, respectively.

Each bar represents the mean (± SD) of determinations from four rats. **, significantly different (p < 0.01) from female rats, as determined by an unpaired Student's t test. *, significantly different (p < 0.05) from female rats, as determined by an unpaired Student's t test.   

    Results and Discussion
Top
Abstract
Introduction
Materials & Methods
Results & Discussion
References

N-VinylPP Production in Male and Female Rats. Previously, when TAO was co-administered with TTMS, N-vinylPP formation was reduced to 34% of control in UT rats, showing that P4503A was the major source of N-vinylPP formation (McNamee and Marks, 1996). It remains to be determined which other P450 isozyme(s) contributed to the formation of N-vinylPP. We hypothesized that, if P4503A2 and 2C11 were major sources of N-vinylPP, female rats would produce much less N-vinylPP than males, because they effectively lack these isozymes (Cooper et al., 1993; Ghosal et al., 1996).

Thus TTMS (111.3 mmol/kg) was injected into male and female rats and 4 hr later the animals were killed and N-vinylPP extracted from their livers and quantitated by a combination of TLC and spectrophotometry. Fig. 2 indicates that female rats produced much less N-vinylPP than males. The N-vinylPP content of female rat liver was 0.034 nmol/g wet weight liver, whereas the N-vinylPP content of the male rat liver was 1.48 nmol/g wet weight liver. If P4503A2 was the only isozyme contributing to N-vinylPP formation, one would anticipate that the amount of N-vinylPP produced in females would be the same as that produced by the TAO-inhibited male, because in both cases P4503A2 is effectively absent. The likely reason for the much lower percentage of N-vinylPP in female rat liver (approximately 2.3% of males) vs. that anticipated from the previous TAO data (34% of control) was the absence of P4502C11 in addition to 3A2 in the female rat liver. Therefore, although P4503A2 is the major isozyme contributing to N-vinylPP formation, P450 2C11 is also a significant contributor. Because P450 2C6 and 2B1/2 exist in relatively equal amounts in male and female rats, and female rats produced much less N-vinylPP than males, these isozymes are not implicated as important contributors to N-vinylPP formation.

Selective Inhibition of P4503A and N-EthylPP Production. Because selective inhibition of P4503A with TAO reduced N-vinylPP production in male rats (McNamee and Marks, 1996), we hypothesized that the same might be true for N-ethylPP production after administration of 4-ethylDDC. Thus, our first experiments were directed to testing the effects of TAO administration on N-ethylPP production in UT- and DEX-pretreated rats after 4-ethylDDC administration. TAO was unable to significantly effect N-ethylPP production in both UT- and DEX-pretreated rats (data not shown). These results indicate that, unlike TTMS, P4503A does not contribute significantly to N-alkylPP production. The fact that the P4503A isozyme is not an important source of N-ethylPP supports previous results obtained by Correia et al. (Correia et al., 1987). These workers suggested that mechanism-based inactivation of P4503A by 4-ethylDDC is accompanied by conversion of the prosthetic heme to products that irreversibly bind to the apoprotein, rather than to N-ethylPP formation.

Induction Study and N-EthylPP Production. Previous studies have shown that, in addition to P4503A, 4-ethylDDC elicits mechanism-based inactivation of rat P450 1A1/2, 2C6, and 2C11 (Riddick et al., 1990; Riddick et al., 1989; Tephly et al., 1986; Correia et al., 1987). To determine which of these isozyme candidates were sources of the N-ethylPP, the effect of several selective P450 inducers, namely beta NF, PB, and DEX, on N-ethylPP production was determined, and the results are shown in fig. 3. In untreated rats, P450 1A1/2 represents only 3%-4% of the total P450 content, whereas, in beta NF-treated animals, the proportions of these isozymes increase to 65%-75% of the total P450 in rat liver (Waxman et al., 1985; Guengerich et al., 1982). Considering that beta NF selectively induces P450 1A1/2 (Waxman et al., 1985), and was the only inducer in our study that increased the amount of N-ethylPP produced, it was inferred that P450 1A1/2 was/were quantitatively important sources of the N-ethylPP in BNF-treated rats. These results support previous studies (Coffman et al., 1982) indicating that induction of P450 1A1/2 with 3-methylcholanthrene increased N-ethylPP formation in rats after administration of 4-ethylDDC. DEX, which increases the functional activity of P4503A 4.2-fold (Wrighton et al., 1985), did not significantly increase the production of N-ethylPP. This observation is consistent with our results (data not shown) demonstrating the inability of TAO-mediated 3A inhibition to decrease N-ethylPP production, and with Correia's results (Correia et al., 1987) indicating that 4-ethylDDC elicits mechanism-based inactivation of P4503A, resulting in apoprotein alkylation rather than N-alkylation of heme and N-ethylPP formation. PB was also unable to significantly affect the production of N-ethylPP, suggesting that the P450 isozymes which it induces (mainly 2B1/2 (Waxman et al., 1985; Swinney et al., 1987)) were not quantitatively important sources of N-ethylPP.


View larger version (11K):
[in this window]
[in a new window]
 
Fig. 3.   Effect of pretreatment of rats with beta NF, DEX, and PB on total N-ethylPP production in rat liver after administration of 4-ethylDDC.

Each bar represents the mean (± SD) of determinations from four rats. *, significantly different (p <0.05) from untreated rats, as determined by a randomized design one-way analysis of variance with the Newman-Keul's post hoc test.

alpha NF Inhibition of P450 1A1/2 and N-EthylPP Production. Because selective induction of P450 1A1/2 increased the amount of N-ethylPP after 4-ethylDDC administration, we hypothesized that selective inhibition of these isozymes should correspondingly decrease production of N-ethylPP. alpha NF is a potent and relatively selective inhibitor of P450 1A1/2 (Chang et al., 1994) and, when administered in conjunction with beta NF, significantly decreased the production of N-ethylPP from 2.49 ± 0.419 nmol/g liver to 0.927 ± 0.600 nmol/g liver, confirming that P450 1A1/2 were important sources of the N-ethylPP in beta NF-treated rats. However, when alpha NF was administered to non-induced rats concurrently with 4-ethylDDC, N-ethylPP formation was not decreased, compared with rats receiving no inhibitor (results not shown). This observation suggests that P4501A/2 are not major sources of N-ethylPP in non-induced rats, which might be attributed to the relatively low levels of these isozymes, approximately 5%, present in untreated rat liver, compared with 65%-70% in beta NF-treated rats (Waxman et al., 1985). Additionally, the possibility that competing P450 isozymes in the untreated rat liver may have a higher catalytic efficiency than P4501A1/2 could account for the apparently low contributions of P450 1A1/2 to N-ethylPP formation in untreated rats.

Because selective P450 isozyme inhibition with alpha NF and TAO ruled out P450 1A1/2 and 3A1/2 as quantitatively important sources of N-ethylPP in untreated rat liver, we hypothesized that other P450 isozymes, namely 2C6 and/or 2C11, were likely the important contributors to N-ethylPP formation. Our next studies were therefore directed to exploring the role of P4502C6 and 2C11 as sources of N-ethylPP formation.

N-EthylPP Production in Male and Female Rats. To examine the roles of P450 2C6 and 2C11 in N-ethylPP formation, 4-ethylDDC was administered to male and female rats, and N-ethylPP was extracted and quantified. Female rats produced 0.081 nmol N-ethylPP/g wet weight liver, which was 22% of the amount produced by male rats, namely 0.3675 nmol N-ethylPP/g wet weight liver (fig. 2). Considering that P4501A1/2 and P4503A2 were excluded as possible sources of the N-ethylPP, and that female rats lack the male-specific isozyme P4502C11 (Morgan et al., 1985; Waxman, 1984), the increased N-ethylPP production seen in male compared with female rats is most likely due to the contributions of P4502C11 in male rat liver. The relatively smaller amount of N-ethylPP that was produced in the female rat liver most likely originated from P4502C6, because 2C11 is absent. Because P4502C6 exists in similar levels in both sexes, we interpreted the N-ethylPP production in females to approximately represent the contribution of P4502C6 to the total N-ethylPP production in males. Thus we conclude that P4502C6 contributes approximately 22% to the total N-ethylPP production, whereas P4502C11 is most likely the source of the remaining 78% in males.

Other investigators have studied the P450 isozymes involved in mechanism-based inactivation and N-ethylPP formation after administration of 4-ethylDDC to rats. Correia (Correia et al., 1987) provided evidence showing that P4503A undergoes prosthetic heme destruction without N-ethylPP formation and suggested that P4502C6 and 2C11 may be the sources of N-ethylPP. Thus, our data, which show that P4502C11 is quantitatively the most important source of N-ethylPP followed by P4502C6, and that P4503A is not an important contributor, support the previous inferences drawn by Correia (Correia et al., 1987).

Comparison of 4-EthylDDC to TTMS. Although both TTMS and 4-ethylDDC elicit mechanism-based inactivation of P450 isozymes 1A1/2, 2C6, 2C11, and 3A, our data shows that different P450 isozymes are quantitatively important for N-alkylPP formation from each of these xenobiotics. The heme moiety of P4502C11 is an important source of both N-ethylPP formation after 4-ethylDDC administration and N-vinylPP formation after TTMS administration. P4503A is a major source of N-vinylPP formation, but does not contribute to N-ethylPP formation. In contrast, the heme moiety of P4502C6 is an important contributor to N-ethylPP but not N-vinylPP formation.

There are several possible reasons for the above differences in the origin of N-alkylPPs. De Matteis et al. (De Matteis et al., 1983) obtained evidence indicating that individual P450 isozymes may give rise preferentially to a different regioisomer (ring A, B, C, or D alkylated; refer to fig. 1) of N-ethylPP after administration of 4-ethylDDC to rats. These investigators explained the formation of different N-alkyl regioisomers as follows: the apoprotein of P450 may either direct the alkyl group liberated from metabolism of 4-ethylDDC on to one of the four pyrrole nitrogens (fig. 1) or cause a change in the state of heme, leading to increased reactivity of a different pyrrole nitrogen. We propose that the apoprotein's influence on alkylation may extend to other regions in addition to the pyrrole nitrogens, namely to targets on the porphyrin nucleus and/or amino acid side chains proximal to the active center. Thus a P450 isozyme's ability or inability to produce N-alkylPPs could depend, in part, on the specific physical properties of its apoprotein, which could lead to the increased susceptibility of the porphyrin nucleus and/or amino acid side chains to alkylation.

The ability of a particular P450 isozyme to produce N-alkylPPs from one xenobiotic and not another may also depend on the mechanism by which the parent compound is oxidatively activated, which is penultimate to N-alkylation. 4-EthylDDC and TTMS undergo conversion to radicals by different mechanisms, and these differences may account for the observation that the important P450 isozyme sources for N-alkylPPs are not the same for each drug. The pathway (fig. 4) to N-ethylPP formation from 4-ethylDDC has been proposed (Ortiz de Montellano, 1989; Augusto et al., 1982; Lee et al., 1988) to first involve a one-electron oxidation of a nitrogen atom (a), resulting in the formation of a radical cation intermediate (b). As this cation aromatizes, an ethyl group is released as a free radical (c), which can alkylate the nearby heme pyrrole nitrogens (d) in close vicinity at the active site. For TTMS, the process by which N-vinylation (fig. 5) occurs has been proposed to involve a more complex pathway (Grab et al., 1988). P450 mediates hydroxylation of the sydnone's heterocyclic ring (a), resulting in ring opening and the liberation of pyruvic acid (b) and the formation of a diazo intermediate (c). After the loss of 2 nitrogen atoms (d), this diazo intermediate forms a double bond with the P450-heme iron. Re-arrangement of the double bond results in an activated carbon atom binding to both the heme iron and one of the pyrrole nitrogens (e); finally, a thio aryl group is eliminated, leaving the N-vinylPP (f).


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 4.   Mechanism of heme N-alkylation by oxidative activation of 4-ethylDDC.

Adapted from Ortiz de Montellano (1989), Augusto et al. (1982), and Lee et al. (1988).


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 5.   Mechanism of heme N-alkylation by oxidative activation of TTMS, as proposed by Ortiz de Montellano and Grab (Grab et al., 1988).

bullet indicates the carbon atoms which eventually form the vinyl group, attached to one of the four pyrrole nitrogens in heme.

The mechanistic differences described above show that a free, albeit short-lived, ethyl radical is formed during decomposition of 4-ethylDDC (Augusto et al., 1982), which could be capable of reacting with targets other than the pyrrole nitrogens. In contrast, a free vinyl radical is not formed during the decomposition of TTMS. These differences may account for the observed ability of P4503A to produce N-vinylPPs from TTMS, while being unable to produce N-ethylPP from 4-ethylDDC. When 4-ethylDDC interacts with the active site of P4503A, the ethyl radical is presumably able to alkylate targets, which ultimately result in heme fragmentation to products that irreversibly bind the apoprotein. In contrast, the pyrrole nitrogens of P4503A may be the only suitable targets for TTMS and N-vinylation, thus preempting possible heme fragmentation. Because P4502C11 is able to produce N-alkyPPs from both 4-ethylDDC and TTMS, we suggest that its active center has readily accessible and/or more reactive pyrrole nitrogens, to facilitate N-alkylation by both xenobiotics. On the other hand, when TTMS interacts with the active site of P4502C6, the propensity for N-alkylation may be decreased because of shielding of the pyrrole nitrogens or reduced reactivity, properties that are dictated by the isozyme's apoprotein.

In summary, the induction of experimental porphyria by two structurally distinct xenobiotics, TTMS and 4-ethylDDC, is dependent on the mechanism-based inactivation of selected P450 isozymes. In untreated rats, for TTMS, the quantitatively important sources of the ferrochelatase-inhibiting N-vinylPPs are P4503A and 2C11; for 4-ethylDDC, P4502C11 and 2C6 are the major contributors to N-ethylPP formation.

    Footnotes

Received December 15, 1997; accepted April 2, 1998.

Supported by the Medical Research Council of Canada.

Send reprint requests to: Gerald S. Marks, Department of Pharmacology and Toxicology, Queen's University, Kingston, Ontario K7L 3N6, Canada.

    Abbreviations

Abbreviations used are: P450, cytochrome P450; N-alkylPP, N-alkylprotoporphyrin IX; 4-ethylDDC, 3,5-diethoxycarbonyl-1,4-dihydro-2,6-dimethyl-4-ethylpyridine; TTMS, 3-[(arylthio)ethyl]sydnone; beta NF, beta -naphthoflavone; alpha NF, alpha -naphthoflavone; PB, phenobarbital; DEX, dexamethasone; TAO, troleandomycin; DMSO, dimethyl sulfoxide; N-ethylPP, N-ethylprotoporphyrin IX; N-vinylPP, N-vinylprotoporphyrin IX.

    References
Top
Abstract
Introduction
Materials & Methods
Results & Discussion
References


0090-9556/98/2608-0739-0744$02.00/0
DRUG METABOLISM AND DISPOSITION
Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
G. P. Black, K. S. Collins, D. P. Blacquiere, and P.-G. Forkert
FORMATION OF N-ALKYLPROTOPORPHYRIN IX FROM METABOLISM OF DIALLYL SULFONE IN LUNG AND LIVER
Drug Metab. Dispos., June 1, 2006; 34(6): 895 - 900.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
J. A. Lavigne, K. Nakatsu, and G. S. Marks
Identification of Human Hepatic Cytochrome P450 Sources of N-alkylprotoporphyrin IX after Interaction with Porphyrinogenic Xenobiotics, Implications for Detection of Xenobiotic-Induced Porphyria in Humans
Drug Metab. Dispos., July 1, 2002; 30(7): 788 - 794.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
S. G. W. Wong, E. H. Lin, and G. S. Marks
Cytochrome CYP Sources of N-Alkylprotoporphyrin IX after Administration of Porphyrinogenic Xenobiotics to Rats
Drug Metab. Dispos., September 1, 1999; 27(9): 960 - 965.
[Abstract] [Full Text]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wong, S. G.W.
Right arrow Articles by Marks, G. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wong, S. G.W.
Right arrow Articles by Marks, G. S.


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition